Literature DB >> 32321732

Remdesivir in covid-19.

Robin E Ferner1, Jeffrey K Aronson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32321732     DOI： 10.1136/bmj.m1610

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  30 in total

Review 1.  Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Viruses       Date:  2020-09-26       Impact factor: 5.048

2.  Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.

Authors:  Carlos K H Wong; Ivan C H Au; Wing Yiu Cheng; Kenneth K C Man; Kristy T K Lau; Lung Yi Mak; Sing Leung Lui; Matthew S H Chung; Xi Xiong; Eric H Y Lau; Benjamin J Cowling
Journal:  Aliment Pharmacol Ther       Date:  2022-03-22       Impact factor: 9.524

Review 3.  Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection.

Authors:  Zhonglei Wang; Liyan Yang
Journal:  Front Pharmacol       Date:  2020-07-02       Impact factor: 5.810

4.  A cohort study of 676 patients indicates D-dimer is a critical risk factor for the mortality of COVID-19.

Authors:  Yongsheng Huang; Xiaoyu Lyu; Dan Li; Lin Wang; Yujun Wang; Wenbin Zou; Yingxin Wei; Xiaowei Wu
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

Review 5.  An integrative look at SARS‑CoV‑2 (Review).

Authors:  Miguel A Ortega; Oscar Fraile-Martínez; Melchor Álvarez-Mon; Ángel Asúnsolo; Basilio De la Torre; Cielo García-Montero; Sandra García-Gallego; Lara Sánchez-Trujillo; Diego Torres-Carranza; Miguel Ángel Álvarez-Mon; Leonel Pekarek; Natalio García-Honduvilla; Julia Bujan
Journal:  Int J Mol Med       Date:  2020-12-22       Impact factor: 4.101

6.  Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality.

Authors:  Fred D Mast; Arti T Navare; Almer M van der Sloot; Jasmin Coulombe-Huntington; Michael P Rout; Nitin S Baliga; Alexis Kaushansky; Brian T Chait; Alan Aderem; Charles M Rice; Andrej Sali; Mike Tyers; John D Aitchison
Journal:  J Cell Biol       Date:  2020-10-05       Impact factor: 8.077

Review 7.  Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies.

Authors:  Arun Samidurai; Anindita Das
Journal:  Int J Mol Sci       Date:  2020-09-16       Impact factor: 5.923

8.  COVID-19: general overview, pharmacological options and ventilatory support strategies.

Authors:  Francesco Menzella; Andrea Matucci; Alessandra Vultaggio; Chiara Barbieri; Mirella Biava; Chiara Scelfo; Matteo Fontana; Nicola Cosimo Facciolongo
Journal:  Multidiscip Respir Med       Date:  2020-11-09

9.  SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target.

Authors:  Bingqing Xia; Xurui Shen; Yang He; Xiaoyan Pan; Feng-Liang Liu; Yi Wang; Feipu Yang; Sui Fang; Yan Wu; Zilei Duan; Xiaoli Zuo; Zhuqing Xie; Xiangrui Jiang; Ling Xu; Hao Chi; Shuangqu Li; Qian Meng; Hu Zhou; Yubo Zhou; Xi Cheng; Xiaoming Xin; Lin Jin; Hai-Lin Zhang; Dan-Dan Yu; Ming-Hua Li; Xiao-Li Feng; Jiekai Chen; Hualiang Jiang; Gengfu Xiao; Yong-Tang Zheng; Lei-Ke Zhang; Jingshan Shen; Jia Li; Zhaobing Gao
Journal:  Cell Res       Date:  2021-06-10       Impact factor: 46.297

Review 10.  Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.

Authors:  Heng Wee Tan; Yan-Ming Xu; Andy T Y Lau
Journal:  Rev Med Virol       Date:  2020-06-30       Impact factor: 11.043
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.